[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622094":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":13,"locations":19,"responsibleParty":51,"collaborators":10,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":22,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Serum Institute of India Pvt. Ltd.","INDUSTRY",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"NmCV-5",null,{"label":12,"type":10,"description":10,"interventionNames":10},"MenACWY-D",[14],{"name":15,"role":16,"phone":17,"phoneExt":10,"email":18},"Dr Prasad Kulkarni, MD, FRCP","CONTACT","+91-20-71946820","drpsk@seruminstitute.com",[20,37],{"facility":21,"status":22,"city":23,"state":10,"zip":10,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Centre pour le Développement des Vaccins du Mali, ex-Institut Marchoux, Ministry of Health, BP251 Bamako, Mali BP251","RECRUITING","Bamako","Mali","ML",{"type":27,"coordinates":28},"Point",[29,30],-7.97522,12.60915,{"lat":30,"lon":29},[33],{"name":34,"role":16,"phone":35,"phoneExt":10,"email":36},"Samba Sow, MD, MSc","+223 20 23 6031","ssow@cvd-mali.org",{"facility":38,"status":22,"city":39,"state":10,"zip":10,"country":40,"countryCode":10,"cosmosGeoPoint":41,"geoPoint":45,"contacts":46},"Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia","Banjul","The Gambia",{"type":27,"coordinates":42},[43,44],-16.57803,13.45274,{"lat":44,"lon":43},[47],{"name":48,"role":16,"phone":49,"phoneExt":10,"email":50},"Dr. Olubukola Idoko, MB BS, MSc, PhD","+220 449 5443","Olubukola.Idoko@lshtm.ac.uk",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100622094",false,"NCT07379151","Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","Evaluation of the Antibody Persistence in African Participants Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","PERS-ACYWX-03","Inclusion Criteria:\n\n* Written informed consent and assent (if applicable)\n\nExclusion Criteria:\n\n* Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination\n* Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study",true,"ALL","7 Years","36 Years",{"count":65,"type":66},450,"ESTIMATED","1 Day","OBSERVATIONAL","This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.",[71],"Meningoccocal Disease",[73,74],"Seropersistence","Meningococcal","2026-05-29",{"date":77,"type":78},"2026-06-03","ACTUAL",{"date":80,"type":78},"2026-05-05",{"date":82,"type":66},"2026-12",{"name":5,"class":6},2]